Medinex Healthcare Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medinex Healthcare Pharmaceutical Export Portfolio Dataset — 4 Products, $22.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medinex Healthcare — Pharmaceutical Exporter Profile (2026) | 4 Products, $22.8K Trade | TransData Nexus

Medinex Healthcare

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $22.8K Total Trade · DGFT Verified

Medinex Healthcare is an Indian pharmaceutical exporter with a total trade value of $22.8K across 4 products in 1 therapeutic categories. Based on 44 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Busulfan ($9.8K), Axitinib ($6.4K), Cabozantinib ($4.5K).

Medinex Healthcare — Export Portfolio & Destination Treemap

Medinex Healthcare pharmaceutical export portfolio — 4 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medinex Healthcare? — Company Overview & Market Position

Medinex Healthcare Private Limited, established on December 30, 2015, is a private limited company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U33110DL2015PTC289022. It operates in the healthcare sector, focusing on the manufacturing and trading of pharmaceutical products. The authorized capital of the company is ₹1,000,000, with a paid-up capital of ₹100,000.

Medinex Healthcare has a significant presence in the Indian pharmaceutical industry, with annual sales exceeding ₹50 lakh and a network of over 400 associated doctors. The company's mission is to meet the expectations of its business partners by supplying and manufacturing products that adhere to regulatory authorities' requirements. Its vision is to be recognized as the most trusted partner for delivering quality products globally.

What Does Medinex Healthcare Export? — Product Portfolio Analysis

Top Products by Export Value

1Busulfan$9.8K 2Axitinib

Product Portfolio — Top 4 by Export Value

Medinex Healthcare exports 4 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Busulfan	Advanced Oncology	$9.8K	3	0.2%	9
2	Axitinib	Advanced Oncology	$6.4K	9	6.8%	4
3	Cabozantinib	Advanced Oncology	$4.5K	20	3.5%	7
4	Lomustine	Advanced Oncology	$2.2K	12	2.1%	12

Medinex Healthcare exports 4 pharmaceutical products across 1 therapeutic categories with a total export value of $22.8K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Medinex Healthcare — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Medinex Healthcare operates manufacturing facilities that are WHO-GMP and ISO 9001:2015 certified, ensuring adherence to international quality standards. The company has obtained written confirmation as per EU norms for several products, including Adrenaline Tartrate, Noradrenaline Tartrate, Carbazochrome, Hydrochlorothiazide, Dimenhydrinate, Glutamic Acid, and L-Glutamic Acid Hydrochloride. Additionally, its state-of-the-art facility is approved by COFEPRIS, the Mexican Health Regulatory Authority.

3Key Leadership

The leadership team at Medinex Healthcare includes:

Aadesh Chaurasia: Managing Director

Ravi Shankar: Director

Vimal Kumar: Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medinex Healthcare Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medinex Healthcare has made significant strides in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold WHO-GMP and ISO 9001:2015 certifications, which are recognized by regulatory authorities in these regions. Furthermore, the company has obtained written confirmation as per EU norms for several products, facilitating market access in European countries. The approval by COFEPRIS further demonstrates the company's compliance with international standards, potentially easing entry into other regulated markets.

2Emerging Markets

Medinex Healthcare has expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-GMP and ISO 9001:2015 certifications, along with written confirmations as per EU norms, enhance its credibility and facilitate market access in these regions. Additionally, the approval by COFEPRIS positions the company favorably for potential collaborations and market penetration in Latin American countries.

3Geographic Strategy

Medinex Healthcare — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Medinex Healthcare's manufacturing facilities are WHO-GMP and ISO 9001:2015 certified, which are recognized by the U.S. Food and Drug Administration (FDA). The company has obtained written confirmation as per EU norms for several products, facilitating market access in European countries. While specific FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's adherence to international quality standards positions it favorably for potential FDA approvals.

2WHO & EU GMP

Medinex Healthcare's manufacturing facilities hold WHO-GMP and ISO 9001:2015 certifications, ensuring compliance with international quality standards. The company has obtained written confirmation as per EU norms for several products, including Adrenaline Tartrate, Noradrenaline Tartrate, Carbazochrome, Hydrochlorothiazide, Dimenhydrinate, Glutamic Acid, and L-Glutamic Acid Hydrochloride. Additionally, its state-of-the-art facility is approved by COFEPRIS, the Mexican Health Regulatory Authority.

3CDSCO & Indian Regulatory

Medinex Healthcare — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medinex Healthcare operates in the competitive pharmaceutical industry, focusing on the export, supply, and contract manufacturing of anti-cancer drugs, life-saving drugs, and other specialty medicines. The company's adherence to international quality standards, including WHO-GMP and ISO 9001:2015 certifications, and approvals from regulatory bodies such as COFEPRIS, positions it favorably in the market. While specific market share data is not publicly available, the company's extensive experience and commitment to quality make it a reputable player in the industry.

2Key Differentiators

Medinex Healthcare's key differentiators include its adherence to international quality standards, such as WHO-GMP and ISO 9001:2015 certifications, and approvals from regulatory bodies like COFEPRIS. The company's focus on anti-cancer drugs, life-saving drugs, and other specialty medicines, along with its extensive experience in the pharmaceutical industry, further distinguishes it in the market.

3Strategic Position

Medinex Healthcare's strategic direction involves a strong focus on the Indian market, with plans to expand operations into other parts of India, such as Orissa, Uttar Pradesh, Madhya Pradesh, Rajasthan, Assam, Haryana, and the National Capital Region (NCR), aiming to establish a pan-Indian presence by 2030. The company's adherence to international quality standards and approvals from regulatory bodies positions it favorably for potential international expansion. The company's focus on anti-cancer drugs, life-saving drugs, and other specialty medicines aligns with global healthcare needs, suggesting a strategic direction towards addressing critical medical conditions.

Buyer Due Diligence Brief — Evaluating Medinex Healthcare as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medinex Healthcare has a track record of supplying a range of pharmaceutical products, including anti-cancer drugs, life-saving drugs, and other specialty medicines. The company's adherence to international quality standards, such as WHO-GMP and ISO 9001:2015 certifications, and approvals from regulatory bodies like COFEPRIS, indicates a commitment to quality and reliability. The company's extensive experience in the pharmaceutical industry and its focus on meeting regulatory requirements further enhance its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Medinex Healthcare as a supplier:

WHO-GMP Certification: Ensures compliance with World Health Organization Good Manufacturing Practices.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Medinex Healthcare

How many pharmaceutical products does Medinex Healthcare export from India?

Medinex Healthcare exports 4 pharmaceutical products across 1 therapeutic categories. The top exports are Busulfan ($9.8K), Axitinib ($6.4K), Cabozantinib ($4.5K), Lomustine ($2.2K). Total export value is $22.8K.

What is Medinex Healthcare's total pharmaceutical export value?

Medinex Healthcare's total pharmaceutical export value is $22.8K, based on 44 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Medinex Healthcare cover?

Medinex Healthcare exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 4 products).

Get Full Medinex Healthcare Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.